Goldman Sachs
IMGN

Goldman Sachs’s Immunogen Inc IMGN Stock Holding History

Goldman Sachs’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-500
Closed -$5K – 5842
2018
Q2 		$5K Sell
500
-7,700
-94% -$81.2K ﹤0.01% 5588
2018
Q1 		$86K Sell
8,200
-21,700
-73% -$214K ﹤0.01% 5331
2017
Q4 		$192K Sell
29,900
-68,800
-70% -$424K ﹤0.01% 5448
2017
Q3 		$755K Buy
98,700
+36,500
+59% +$243K ﹤0.01% 4807
2017
Q2 		$442K Buy
62,200
+49,000
+371% +$224K ﹤0.01% 5191
2017
Q1 		$51K Buy
13,200
+6,300
+91% +$18.4K ﹤0.01% 6284
2016
Q4 		$14K Sell
6,900
-6,700
-49% -$13.5K ﹤0.01% 6718
2016
Q3 		$36K Buy
13,600
+2,800
+26% +$8.14K ﹤0.01% 6584
2016
Q2 		$33K Sell
10,800
-96,200
-90% -$603K ﹤0.01% 6565
2016
Q1 		$912K Buy
107,000
+73,900
+223% +$625K ﹤0.01% 4152
2015
Q4 		$449K Sell
33,100
-11,000
-25% -$135K ﹤0.01% 5017
2015
Q3 		$423K Sell
44,100
-16,900
-28% -$247K ﹤0.01% 5314
2015
Q2 		$877K Sell
61,000
-1,500
-2% -$16.5K ﹤0.01% 4657
2015
Q1 		$559K Sell
62,500
-140,000
-69% -$1.01M ﹤0.01% 5016
2014
Q4 		$1.24M Buy
202,500
+83,500
+70% +$764K ﹤0.01% 4344
2014
Q3 		$1.26M Buy
119,000
+104,900
+744% +$1.19M ﹤0.01% 4380
2014
Q2 		$167K Sell
14,100
-4,500
-24% -$56.5K ﹤0.01% 6323
2014
Q1 		$278K Sell
18,600
-6,900
-27% -$109K ﹤0.01% 5802
2013
Q4 		$374K Sell
25,500
-17,200
-40% -$264K ﹤0.01% 5525
2013
Q3 		$727K Buy
42,700
+9,600
+29% +$169K ﹤0.01% 4847
2013
Q2 		$549K Buy
+33,100
New +$536K ﹤0.01% 4866

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's IMGN Position: Q1 2024 in Review

Goldman Sachs sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 1,189,485 shares — an estimated $35.3M sold.

Goldman Sachs first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $35.3M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Goldman Sachs reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 1,189,485 Immunogen Inc shares in Q1 2024, an estimated $35.3M.
  • Goldman Sachs first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
  • Goldman Sachs's Immunogen Inc position peaked at $35.3M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.